FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to prodrug compounds of formula I:
I, wherein: R2 and R3 independently represent hydrogen, halogen or C1-C6-alkyl, where said C1-C6-alkyl is substituted with 0–6 halogen atoms; R5 is hydrogen, halogen, OH or C1-C6-alkyl, where said C1-C6-alkyl is substituted with 0–6 halogen atoms and where up to two non-adjacent links of CH2 said C1-C6-alkyl can be replaced with -O-; R7 is hydrogen, halogen or C1-C6-alkyl, where said C1-C6-alkyl is substituted with 0–6 halogen atoms and where up to two non-adjacent links of CH2 said C1-C6-alkyl can be replaced with -O-; and X is -PO(OH)2, -PO(OH)O-M+, -PO(O-)2⋅2M+ or -PO(O-)2D2+; M+ is a pharmaceutically acceptable monovalent cation; and D2+ is a pharmaceutically acceptable bivalent cation; which are used for treating various disorders, including pain.
EFFECT: prodrugs of pyridonamides used as modulators of sodium channels are proposed.
74 cl, 6 dwg, 9 tbl, 15 ex
Title | Year | Author | Number |
---|---|---|---|
PYRIDONAMIDE PRODRUGS USED AS SODIUM CHANNELS MODULATORS | 2014 |
|
RU2811402C2 |
AMIDES AS MODULATORS OF SODIUM CHANNELS | 2014 |
|
RU2658920C2 |
AMIDES OF CONDENSED PIPERIDINE AS MODULATORS OF ION CHANNELS | 2014 |
|
RU2741810C2 |
PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | 2014 |
|
RU2662223C2 |
SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | 2014 |
|
RU2680401C2 |
PYRIDONAMIDES AS SODIUM CHANNELS MODULATORS | 2014 |
|
RU2808424C2 |
ION CHANNEL INHIBITORS, PHARMACEUTICAL FORMULATIONS AND APPLICATIONS | 2016 |
|
RU2746188C2 |
BENZAMIDE COMPOUNDS | 2019 |
|
RU2801647C2 |
TRKA KINASE INHIBITORS, COMPOSITIONS BASED THEREON AND METHODS | 2015 |
|
RU2672583C2 |
SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH DERIVATIVE | 2006 |
|
RU2394560C2 |
Authors
Dates
2019-06-27—Published
2014-12-12—Filed